World Leader in Hand-held, 3D, In Vivo, Sub-cellular Imaging
Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing and commercialisation of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, 3D, in vivo imaging at the sub-cellular level.
We have a strong purpose of transforming people’s lives through the earlier and less invasive diagnosis and treatment of cancer and are on a journey to achieve this globally. We strive to give healthcare providers and researchers the highest quality in-vivo microscopic imaging tools to enable the early detection and management of disease, in order to improve patient outcomes and reduce the high cost of curative medicine.
Our technology, used by leading research institutions and hospitals in North America, Europe, Asia and Australia enables real-time, in vivo imaging at the cellular level in human and animal tissue. Our technology is at the heart of the Carl Zeiss Meditec CONVIVO device used successfully in neurosurgery. In collaboration with Pentax Medical, we released the first-ever human confocal endomicroscope for gastroenterology.
Our FIVE2 ViewnVivo system builds upon our previously successful FIVE1 platform with enhanced 3D imaging features enabling virtual biopsies in living, breathing, moving tissue. New applications in the identification of dysplastic and diseased tissue, tumour margins, molecular disease markers, women’s health, veterinary and research applications are being developed in association with world-leading institutions. The system’s flexibility facilitates research in applications including live imaging of dynamic processes, assessment of dysplastic and malignant tissue, tumour margin mapping, imaging of molecular disease markers, blood flow and clots, barrier function, infection and pharmacokinetics across tissue types and organ systems.
Collaborations with Multinational Medical Technology Companies and Clinical Applications
Our goal is to support medical practitioners and researchers with imaging tools that provide real-time information about the health of living tissue in a diverse range of diseases, with the aim of providing better health outcomes for patients and overall savings in time and money for the healthcare system.
Optiscan is developing the usage of its technology in various surgical areas both in its own right and in collaboration with leading medical technology companies. Optiscan’s patented technology has been integrated into a number of clinical systems marketed by leading medical technology companies including Carl Zeiss Meditec and Pentax Medical.
Optiscan and Carl Zeiss Meditec continue to collaborate on the development and commercialisation of a miniaturised confocal endomicroscope for neurosurgery, known as the CONVIVO system. The device provides a real-time “virtual biopsy” during a clinical procedure, assisting pathologists and surgeons to determine cancerous and non-cancerous tissue and visualise tumour margins. FDA 510(k) clearance and CE Mark for the CONVIVO has been received and the regulatory pathway for other markets is progressing.
Optiscan has previously collaborated with Pentax Medical in relation to the development and distribution of the world’s first human confocal endomicroscope for gastroenterology.
Optiscan is currently working on clinical studies and other research in relation to oral and breast cancer applications and is investigating additional applications in other areas.